stringtranslate.com

Robert S. Rosenson

Dr. Robert S. Rosenson is a Professor of Medicine and also lending his services as the Director of cardio metabolic disorders at the Icahn School of Medicine at Mount Sinai.[2]

Education

Dr. Robert S. Rosenson earned his medical degree from Tulane University. He did his residency in internal medicine at the Brigham and women’s hospital, Harvard medical school and obtained a fellowship in cardiovascular medicine at the University of Chicago hospital.[3][4]

Research and career

Dr. Robert S. Rosenson studies the effects of lipid-lowering therapy in different regions of the United States.[5] He researches selective inhibitors of inflammatory pathways such as lipoprotein-associated with phospholipase A2,[6] and also did research on the efficacy and safety of evolocumab in patients with type 2 diabetes mellitus and hypercholesterolemia.[7]

Dr. Robert Rosenson served as the Director of the Preventive Cardiology Center at Rush-Presbyterian-St. Luke’s Medical Center.[8] At the University Of Michigan School Of Medicine, he served as the Director of the lipoprotein disorders and clinical atherosclerosis research.[9] Now, he is currently serving at the Mount Sinai Icahn School of Medicine as a Professor of Medicine.[10]

Awards and honors

Dr. Robert S. Rosenson was the recipient of the 2019 Clinician/Educator Award by the National Lipid Association. Additional awards include the Ground-Breaking Doctors Award from Chicago Magazine,[11] Simon Dack Award,[12] and received the Jan. J. Kellerman Memorial Award in 2016.[13]

He is a fellow of a number of committees include the American College of Cardiology, American College of Physicians, American Heart Association Council on Epidemiology and Prevention, European Society of Cardiology, and National Lipid Association.[14][15]

Publications

References

  1. ^ "rosenson". mountsinai.org.
  2. ^ "Robert Rosenson | Icahn School of Medicine". Icahn School of Medicine at Mount Sinai. Retrieved 2019-12-18.
  3. ^ "Robert Rosenson | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2019-12-18.
  4. ^ "Robert Rosenson, Cardiovascular Disease Doctor in New York, NY". doctor.webmd.com. Retrieved 2019-12-18.
  5. ^ Ballantyne, Christie M.; Cannon, Christopher; Lemos, James de; Rosenson, Robert; Philip, Kiran; Mues, Katherine; Alam, Shusama; Liu, Yuyin; Bhatt, Deepak L.; Kosiborod, Mikhail (2019-03-12). "Lipid-Lowering Therapy in Different Regions of the United States: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (gould): A Registry of High Cardiovascular Risk Patients in the United States". Journal of the American College of Cardiology. 73 (9 Supplement 1): 1834. doi:10.1016/S0735-1097(19)32440-4. ISSN 0735-1097.
  6. ^ Garg, Parveen K.; Bartz, Traci M.; Norby, Faye L.; Jorgensen, Neal W.; McClelland, Robyn L.; Ballantyne, Christie M.; Chen, Lin Y.; Gottdiener, John S.; Greenland, Philip; Hoogeveen, Ron; Jenny, Nancy S. (2018-03-01). "Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts". American Heart Journal. 197: 62–69. doi:10.1016/j.ahj.2017.11.010. ISSN 0002-8703. PMC 5860682. PMID 29447785.
  7. ^ Rosenson, Robert S.; Daviglus, Martha L.; Reaven, Peter; Pozzilli, Paolo; Bays, Harold; Monsalvo, Maria Laura; Elliott, Mary; Somaratne, Ransi; Handelsman, Yehuda (2018-07-01). "Efficacy and Safety of Evolocumab in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia or Mixed Dyslipidemia". Diabetes. 67 (Supplement 1): 128–OR. doi:10.2337/db18-128-OR. ISSN 0012-1797. S2CID 90804054.
  8. ^ "Blood Is Less Sticky With Estrogen Replacement Therapy". ScienceDaily. Retrieved 2019-12-18.
  9. ^ "Dr. Rosenson on Cholesterol". Health.com. Retrieved 2019-12-18.
  10. ^ "Robert Rosenson, MD". www.cardiometabolichealth.org. Retrieved 2019-12-18.
  11. ^ "Advisors Committee". HARTIS Pharma. Retrieved 2019-12-18.
  12. ^ "Robert Rosenson, MD". www.cardiometabolichealth.org. Retrieved 2019-12-18.
  13. ^ Dr. Robert Rosenson: Cholesterol therapy in high-risk CHD patients, retrieved 2019-12-18
  14. ^ "Robert S. Rosenson - Chief, Director, Professor of Cardiology, Internal Medicine in New York, New York, United States of America | eMedEvents". www.emedevents.com. Retrieved 2019-12-18.
  15. ^ "Robert S. Rosenson". TMA - Translational Medicine Academy. Retrieved 2019-12-18.
  16. ^ Rosenson, Robert S.; Tangney, Christine C. (1998-05-27). "Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction". JAMA. 279 (20): 1643–1650. doi:10.1001/jama.279.20.1643. ISSN 0098-7484. PMID 9613915.
  17. ^ Rosenson, R. S.; Brewer, H. B.; Chapman, M. J.; Fazio, S.; Hussain, M. M.; Kontush, A.; Krauss, R. M.; Otvos, J. D.; Remaley, A. T.; Schaefer, E. J. (2011-03-01). "HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events". Clinical Chemistry. 57 (3): 392–410. doi:10.1373/clinchem.2010.155333. ISSN 0009-9147. PMID 21266551.
  18. ^ Rosenson Robert S.; Brewer H. Bryan; Davidson W. Sean; Fayad Zahi A.; Fuster Valentin; Goldstein James; Hellerstein Marc; Jiang Xian-Cheng; Phillips Michael C.; Rader Daniel J.; Remaley Alan T. (2012-04-17). "Cholesterol Efflux and Atheroprotection". Circulation. 125 (15): 1905–1919. doi:10.1161/CIRCULATIONAHA.111.066589. PMC 4159082. PMID 22508840.
  19. ^ Rosenson, Robert S.; Otvos, James D.; Freedman, David S. (2002-07-15). "Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trial". American Journal of Cardiology. 90 (2): 89–94. doi:10.1016/S0002-9149(02)02427-X. ISSN 0002-9149. PMID 12106834.